Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

Gurbaxani B, Dostalek M, Gardner I.

Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2. Review.

PMID:
23917469
2.

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T.

J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.

3.

Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.

Pollastrini J, Dillon TM, Bondarenko P, Chou RY.

Anal Biochem. 2011 Jul 1;414(1):88-98. doi: 10.1016/j.ab.2011.03.001. Epub 2011 Mar 6.

PMID:
21385563
4.

Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.

Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T.

Drug Metab Dispos. 2011 Sep;39(9):1469-77. doi: 10.1124/dmd.111.039453. Epub 2011 May 24.

5.

Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.

Chen Y, Balthasar JP.

AAPS J. 2012 Dec;14(4):850-9. doi: 10.1208/s12248-012-9395-9. Epub 2012 Sep 7.

6.

Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.

Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V.

J Immunol Methods. 2013 Apr 30;390(1-2):81-91. doi: 10.1016/j.jim.2013.01.011. Epub 2013 Feb 4.

PMID:
23384837
7.

A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).

Ferl GZ, Wu AM, DiStefano JJ 3rd.

Ann Biomed Eng. 2005 Nov;33(11):1640-52. Erratum in: Ann Biomed Eng. 2011 Oct;39(10):2668.

PMID:
16341929
8.

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.

Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ.

MAbs. 2015;7(6):1084-93. doi: 10.1080/19420862.2015.1075109. Epub 2015 Sep 4.

9.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

10.

Characterization and screening of IgG binding to the neonatal Fc receptor.

Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, Tiller T, Brocks B, Ostendorp R, Pabst S.

MAbs. 2014 Jul-Aug;6(4):928-42. doi: 10.4161/mabs.28744. Epub 2014 Apr 7.

11.

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.

Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A.

MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15.

12.

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB.

J Immunol. 2009 Jun 15;182(12):7663-71. doi: 10.4049/jimmunol.0804182.

13.

A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.

Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, Hertenberger H, Wolfert A, Spick C, Lau W, Drabner G, Reiff U, Koll H, Papadimitriou A.

MAbs. 2014;6(5):1229-42. doi: 10.4161/mabs.29601. Epub 2014 Oct 30.

14.

FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.

Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ.

Drug Metab Dispos. 2012 Aug;40(8):1545-55. doi: 10.1124/dmd.112.045864. Epub 2012 May 14.

15.

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.

Wang Y, Tian Z, Thirumalai D, Zhang X.

J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. Review.

PMID:
24404896
16.

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.

Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A.

MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353.

17.

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.

Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002. doi: 10.1073/pnas.1408766112. Epub 2015 Apr 27.

18.

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.

Souders CA, Nelson SC, Wang Y, Crowley AR, Klempner MS, Thomas W Jr.

MAbs. 2015;7(5):912-21. doi: 10.1080/19420862.2015.1054585.

19.

Application of FcRn binding assays to guide mAb development.

Datta-Mannan A, Wroblewski VJ.

Drug Metab Dispos. 2014 Nov;42(11):1867-72. doi: 10.1124/dmd.114.059089. Epub 2014 Jul 14. Review.

20.

Targeting FcRn for the modulation of antibody dynamics.

Ward ES, Devanaboyina SC, Ober RJ.

Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9. Review.

Supplemental Content

Support Center